The incidence of stroke-heart syndrome following acute stroke, which encompasses both acute ischemic stroke and acute intracerebral hemorrhage, is notably high and is strongly associated with increased mortality and poor outcomes in stroke patients. However, the underlying mechanisms remain unclear, and there are currently no effective prevention or treatment strategies. This study aims to elucidate the neuro-humoral mechanisms of stroke-heart syndrome through multimodal imaging and multi-omics blood analysis. Additionally, it seeks to observe the progression of stroke-heart syndrome and its impact on functional outcomes, cognitive abilities, and emotional issues post-stroke. The research is expected to uncover novel blood biomarkers and brain network mechanisms associated with stroke-heart syndrome, providing potential targets and theoretical foundations for pharmacological treatments or physical interventions. Furthermore, it aims to establish a risk early-warning system for major cardiovascular complications post-stroke, enabling early identification, early intervention, and integrated brain-heart management to improve clinical outcomes for stroke patients.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Patients admitted within 48 hours of onset, confirmed by CT/MRI as having a stroke (including acute ischemic stroke and hemorrhagic stroke).
2. Moderate-to-severe stroke with NIHSS ≥ 5.
Exclusion Criteria:
1. Previous focal brain injury (such as stroke, brain surgery, traumatic brain injury, etc.).
2. Brain dysfunction caused by other major neurological disorders than stroke (such as brain tumors, epilepsy, Parkinson's disease, etc.).
3. Transient ischemic attack (TIA) and subarachnoid hemorrhage (SAH).
4. History of cardiac diseases (such as coronary heart disease, heart failure, severe arrhythmias, congenital heart disease, cardiac surgery, valvular heart disease, or undiagnosed significant cardiac symptoms).
5. Concomitant systemic diseases such as renal failure (eGFR \< 30), autoimmune disorders, severe infections, etc.
6. History of dementia, depression, or other psychiatric disorders.
7. Poor compliance and inability to cooperate with follow-up.
Primary outcome measure(s)
blood high-sensitivity cardiac troponin level — within 48 hours and at 72 hours after stroke onset a marker of acute myocardial injury
left ventricular ejection fraction — within 1 week after stroke onset measured by transthoracic echocardiography; a marker of ventricular dysfunction and heart failure
blood N-terminal pro-brain natriuretic peptide (NT-proBNP) level — within 1 week after stroke onset a marker of ventricular dysfunction and heart failure
functional outcome — 3 months and 1 year after stroke onset. measured by modified Rankin scale (mRS), a 7-level ordinal scale (scores 0-6) used to assess global disability after stroke. Higher scores indicate worse functional outcome.
death — 1 month, 3 months and 1 year after stroke onset
Trial sites (1)
Facility
City
Region
Status
Department of Neurology, Tongji hospital, Tongji medical college, Huazhong University of Science and Technology
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.